|Application ||WB, E|
|Calculated MW||52346 Da|
|Antigen Region||98-125 aa|
|Other Names||Ral-GDS-related protein, hRGR, Ral guanine nucleotide dissociation stimulator-like 4, RalGDS-like 4, RGL4, RGR|
|Target/Specificity||This RGL4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 98-125 amino acids from the N-terminal region of human RGL4.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||RGL4 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Cytoplasmic vesicle.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Ral GDS (Ral guanine nucleotide dissociation stimulator) is a guanine nucleotide exchange factor (GEF) that activates Ral and is implicated in oncogenic Ras-induced cell transformation. RGL4 (ral guanine nucleotide dissociation stimulator-like 4), also known as Rgr, is a 473 amino acid protein that localizes to the cytoplasmic vesicle of cells. Belonging to the GEF family of proteins, RGL4 induces phosphorylation of ERKs, p38 and JNK kinases, and it increases the levels of GTP bound forms of Ral and Ras. Ras activation is crucial for the transforming activity of RGL4. Due to its similarity to Ral GDS, RGL4 may be implicated in carcinogenesis.
Hernandez-Munoz, I., et al. Cancer Res. 63(14):4188-4195(2003)
Hernandez-Munoz, I., et al. Oncogene 19(23):2745-2757(2000)
Dunham, I., et al. Nature 402(6761):489-495(1999)
D'Adamo, D.R., et al. Oncogene 14(11):1295-1305(1997)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.